small cap stocks « AGORACOM Small-cap Investor Relations Blog

Posts Tagged ‘small cap stocks’

Empower Clinics $CBDT.ca $EPWCF Signs Definitive Agreement to Acquire Momentum Health With 7 Canadian Clinics. Begins Planning for Nationwide Rollout $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 4:16 PM on Thursday, December 17th, 2020

Acquisition Will Expand Company’s North American Footprint And Strengthen Vertical Integration From Patients To Laboratory, Strengthening Testing and Bubble Initiatives

Announced the execution of a definitive share purchase agreement dated December 16, 2020 to acquire Lawrence Park Health and Wellness Clinic Inc., 1100900 Canada Inc. dba Atkinson, and Momentum Health Inc.
Momentum Health operates a network of medical clinics with a team of healthcare professionals who provide para-medical care by applying a holistic and hands-on approach working with patients to unlock potential well-being.
Key services include physiotherapy, chiropractic, massage therapy, traditional Chinese medicine, athletic therapy and others.
Acquisition will include two standalone wellness clinics and five new co-located clinics in the Greater Toronto Area of Ontario, Canada, with immediate access to in excess of 20,000 patients.

VANCOUVER, BC / December 17, 2020 / Empower Clinics (CSE:CBDT)(OTC PINK:EPWCF)(FRA:8EC) (the “Company” or “Empower”), an integrated healthcare company serving patients through clinics, a telemedicine platform, and a leading medical diagnostics laboratory processing thousands of COVID-19 specimens and developing novel COVID-19 testing protocols for CE, FDA and Health Canada approval, is pleased to announce the execution of a definitive share purchase agreement dated December 16, 2020 (the “Agreement“) to acquire Lawrence Park Health and Wellness Clinic Inc., 1100900 Canada Inc. dba Atkinson, and Momentum Health Inc. (collectively “Momentum Health“).

Steven McAuley, Chairman and CEO of Empower stated “The acquisition of Momentum Health will be a significant milestone for both Empower and its shareholders that we expect will provide Empower with a growing accretive business, as well as, a winning business model with plans for immediate expansion across the Greater Toronto Area, the province of Ontario and then nationwide in very rapid succession. It is anticipated that this immediate and rapid nationwide expansion plan will be made possible by combining the winning Momentum Health model with the financial, marketing and operational control resources already successfully deployed by Empower in building its US operations, including the successful win of a $1.2 million testing contract with a film and television studio within just 45 days of acquiring our KAI Medical Lab. Significant discussions are already underway with potential nationwide partners and we expect to have developments in the very near future.”

ACQUISITION INCLUDES 7 CLINICS IN GREATER TORONTO AREA WITH IMMEDIATE PLANS TO EXPAND “CLINIC-IN-CLINIC” MODEL ACROSS CANADA.

Momentum Health operates a network of medical clinics with a team of healthcare professionals who provide para-medical care by applying a holistic and hands-on approach working with patients to unlock potential well-being. Key services include physiotherapy, chiropractic, massage therapy, traditional Chinese medicine, athletic therapy and others. The full range of services can be viewed at www.momentumhealthclinic.com.

The acquisition will include two standalone wellness clinics and five new co-located clinics in the Greater Toronto Area of Ontario, Canada, with immediate access to in excess of 20,000 patients.

More importantly, it is expected that expansion will be at a very attractive and cost-effective model of opening “clinics-within-clinics” in which the Company proposes to partner with large care facilities to provide para-medical clinics inside the physical location of the primary care facility. This model results in a win-win for both Empower and the primary care facility partner as follows:

Substantially improved care for patients of the primary care facility
Significantly reduced start-up costs for Empower
Immediate access to the large patient base of the primary care facility
Immediate rental income for the primary care facility

With this proven winning model, the nationwide roll-out it is planned to commence immediately upon closing of the acquisition with expansion in the Greater Toronto Area, followed by expansion throughout Ontario and finally West through all Provinces with a standardized brand and technology platform.

Moreover, the acquisition includes incentives for the two Co-Founders of Momentum Health to open an additional 30 clinics across Canada.

CEO McAuley added “Having Dr. Rabinowitz and Dr. Tsimerman join me in leadership to rapidly expand Empower’s clinic footprint across Canada will be invaluable toward meeting our ambitious objectives.”

Momentum Co-Founder Dr. Robinowitz commented “Joining Empower provides us with the opportunity to scale an intricately designed health care model alongside the outstanding professionals currently on their team. This transaction will not only allow our current patients to have increased access to integrative care, we also strive to exponentially increase our patient base with strategic, nationwide expansion.”

Momentum Co-Founder Dr. Tsimerman commented “I am thrilled to be joining Empower Clinics with a shared vision of nationwide, truly integrative medical care based on patient – centric services. This unique opportunity allows us to provide an unparalleled patient experience and create a leading approach to modernized health care.”

TERMS OF ACQUISITION

Pursuant to the terms of the Agreement, Empower will pay the vendors of Momentum Health $275,000 cash at closing (including $44,648 to settle an outstanding debt of Momentum Health) with an additional $75,000 to be withheld as a holdback for adjustments, for an aggregate cash payment of $350,000. In addition, at closing, Empower will issue Dr. Jordan Rabinowitz and Dr. Aviv Tsimerman or their affiliates 5,128,204 common shares in the capital of Empower (at a deemed price of $0.0975 per share), 2,564,102 of which will be subject to contractual resale restrictions resulting in them being released quarterly from the date of closing in eight (8) equal instalments.

PERFORMANCE INCENTIVES TO OPEN 30 ADDITIONAL LOCATIONS

The acquisition also includes long-term performance incentives for Dr. Rabinowitz and Dr. Tsimerman. If, within 18 months from the closing date, the Company or its affiliates have opened and have operating an aggregate of ten (10) new clinic locations in Canada (“Milestone One”), each of Dr. Rabinowitz and Dr. Tsimerman shall be entitled to receive incentive stock options of Empower to purchase 1,875,000 common shares of Empower, vesting as follows:

1/3 immediately;
1/3 upon of the Company or its affiliates having opened and operating an aggregate of twenty (20) new clinic locations in Canada; and
1/3 upon of the Company or its affiliates having opened and operating an aggregate of thirty (30) new clinic locations in Canada.

ADDITIONAL DETAILS

Empower has agreed to enter into employment agreements with Dr. Rabinowitz and Dr. Tsimerman on closing of the acquisition, to lead the Canadian clinic expansion strategy.

Completion of the acquisition contemplated by the Agreement is subject to customary closing conditions which the Company anticipates being completed on or before December 21, 2020.

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

ABOUT EMPOWER:

Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors:
Dustin Klein
Director
[email protected]
720-352-1398

Investors:
Steven McAuley
CEO
[email protected]
604-789-2146

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the Company’s nationwide rollout and timing and results of such rollout; the Company expecting the acquisition will provide Empower with a growing accretive business, as well as, a winning business model with plans for immediate expansion across the Greater Toronto Area, the province of Ontario and then nationwide in very rapid succession; the Company’s expectation for the costs of expansion; and the Company’s plans to partner with large care facilities to provide para-medical clinics inside the physical location of the primary care facility and the results of such model. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Kai Medical Laboratory acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse affect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control; as well as those risk factors discussed or referred to in the Company’s disclosure documents filed with the securities regulatory authorities in certain provinces of Canada and available at www.sedar.com. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

Tags: covid19, Covid19 testing, CSE, Diagnos Inc, investments, Kai Medical Laboratory, small cap stocks, tsx, tsx-v
Posted in All Recent Posts, Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca $EPWCF Signs Definitive Agreement to Acquire Momentum Health With 7 Canadian Clinics. Begins Planning for Nationwide Rollout $WELL.ca $DOC.ca $DOCRF $VMD.ca

Quebec Pharmacists Launch #ECG Screening for the Prevention of Drug Induced Sudden Cardiac Death – CardioComm Solutions $EKG.ca $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

Posted by AGORACOM-JC at 11:04 AM on Thursday, December 17th, 2020

HeartCheck™ CardiBeat and SMART Monitoring ECG Triaging to be used in Screening Services for detection of QT Prolongation in Community Pharmacies

Confirms the start of a pharmacy-based ECG monitoring service to screen for prolonged QT interval for the prevention of drug induced sudden cardiac death.
Under the Company’s Allied Health Professional Partner Program, the HeartCheck™ CardiBeat and GEMS™ Mobile Smartphone app will be used to collect ECGs recorded by patients under the direction of a pharmacist.
Recorded ECGs will be passed from the GEMS™ Mobile app to the Company’s SMART Monitoring ECG reading service to be triaged.
All findings will be sent directly to the pharmacist and any submitted ECG recordings that show a presence of prolonged QT interval or any other cardiac arrhythmia will be flagged so that the pharmacist may then follow up as needed with the patient’s treating physician.

TORONTO, ON / December 17, 2020 / CardioComm Solutions, Inc. (TSXV:EKG) (“CardioComm” or the “Company“), a global provider of consumer heart monitoring and electrocardiogram (“ECG“) device and software solutions, confirms the start of a pharmacy-based ECG monitoring service to screen for prolonged QT interval for the prevention of drug induced sudden cardiac death.

Under the Company’s Allied Health Professional Partner Program, the HeartCheck™ CardiBeat and GEMS™ Mobile Smartphone app will be used to collect ECGs recorded by patients under the direction of a pharmacist. Recorded ECGs will be passed from the GEMS™ Mobile app to the Company’s SMART Monitoring ECG reading service to be triaged. All findings will be sent directly to the pharmacist and any submitted ECG recordings that show a presence of prolonged QT interval or any other cardiac arrhythmia will be flagged so that the pharmacist may then follow up as needed with the patient’s treating physician.

Pharmacists plan to run ECG tests on patients when picking up a prescription. All QT and QTc interval findings will be kept on file with the goal of recording QT measurements for any patient with known cardiac issues and starting any new medication known to influence the QT interval. “As polypharmacy analysis becomes more prevalent in a pharmacist’s daily tasks, the use of the HeartCheck™ CardiBeat device will allow staff to quickly measure the patient’s QT/QTc and make a clinical judgment as per the safety of the prescriptions being dispensed”, states pharmacist K. Manoukian.

QT interval prolongation is a recognized adverse drug reaction and risk factor for torsades de pointes (TdP), a fatal arrhythmia that can result in sudden cardiac death. While rare, the severity of TdP makes QT prolongation a serious concern when prescribing medications.

Pharmacists have a legal and professional responsibility to evaluate/mitigate medication adverse and serious adverse event risk factors and are the final decision makers in dispensing or not dispensing medications. The surface ECG is the only way to confirm or rule out the presence of a prolonged QT interval. The HeartCheck™ CardiBeat provides a useful tool as QT prolongation can now be easily, quickly and cost effectively obtained in community pharmacies and be compared to well established normal duration ranges. Without an ECG sudden cardiac death due to a prolonged QT interval may be the first and only evidence of the disease. Prior to the release of CardioComm’s ECG screening technologies, QT interval prolongation ECG screening was not available outside of the hospital setting.

Listings of medications known to cause TdP through acquired QT syndrome prolongation in healthy people (crediblemeds.org, sads.org.uk and heartcentre.ca) contain more than 100 common medications, many of which are dispensed by pharmacists. These include common antibiotics, medications to treat yeast infections, diuretics, anti-arrhythmia heart medications, and antidepressant and antipsychotic medications. Additionally, COVID-19 infection, a history of cardiac arrest and cardiovascular disease, age and women on heart medications are also known to increase the risk for cause acquired QT interval prolongation.

Through the screening service CardioComm will earn revenue from a per ECG QT interval triaging service fee. With the program now launched in Quebec, the Company will next look to the introduction of the QT interval ECG screening services in pharmacies and physician practices in other provinces.

To learn more about CardioComm’s products and for further updates regarding HeartCheck™ ECG device integrations, please visit the Company’s websites at www.cardiocommsolutions.com and www.theheartcheck.com.

About CardioComm Solutions

CardioComm Solutions’ patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485:2016 MDSAP certification, is HIPAA compliant and holds clearances from the European Union (CE Mark), the USA (FDA) and Canada (Health Canada).

FOR FURTHER INFORMATION PLEASE CONTACT:

Etienne Grima, Chief Executive Officer
1-877-977-9425 x227
[email protected]
[email protected]

Forward-looking statements

This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management’s current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.

In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: CardioComm Solutions, Inc.

Tags: CardioComm SMART Monitoring ECG reading, CSE, ECG, GEMS™ ECG, investments, mhealth, small cap stocks, Smart apps
Posted in CardioComm Solutions | Comments Off on Quebec Pharmacists Launch #ECG Screening for the Prevention of Drug Induced Sudden Cardiac Death – CardioComm Solutions $EKG.ca $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

VIDEO – KWESST Micro Systems $KWE.ca Soldier Launched Micro Drones, Electronic Soldier Decoys and a $1.1 Million Dollar Follow-On Order From A Key US Military Customer $WRTC $BYRN.ca $PAT.ca $POWW

Posted by AGORACOM-JC at 8:45 AM on Thursday, December 17th, 2020

If you haven’t heard of KWESST Micro Systems (KWE:TSXV) you’re not alone because the Company just listed for trading a couple of months ago – and it is probably the coolest new listing of 2020 if you love high-tech, covert defense systems that we only get to see in Tom Cruise movies.

KWESST is a leader in “soldier systems” which are technologies that increase the capabilities of soldiers, Let’s be clear right off the start, KWESST doesn’t sell weaponry. Rather, it sells technologies that make a big difference to the safety and effectiveness of soldiers.

For example, out in a field of combat, soldiers emit Electro Magnetic (EM) signatures that make them detectable by enemy combatants. KWESST has a battlefield decoy system that creates multiple false phantom signatures to spoof adversaries. This picture is worth 1,000 words.

We could go on about many other such technologies created by KWESST but this is AGORACOM after all and we want to get down to the business of KWESST, the highlights of which are as follows:

A developer of next-generation systems for forces around the world, including those of NATO and its allies
A leadership team whose experience spans decades and hundreds of millions of dollars in military and homeland security contracts
A sales and distribution network of agents that spans the globe
Partnerships with globally recognized OEM’s, including Samsung
A sales pipeline that stood at $93,000,000 (not a typo) as of August 2020
Already generating revenues in 2020

And last but not least, a secret weapon in its Executive Chairman David Luxton, whose companies under his leadership have generated over $1,000,000,000 (Yes, BILLION).

The soldier systems market is projected to hit $14.5 Billion by 2023 and, up until now, small cap investors have never had a company to participate in this lucrative (and SUPER COOL) market.

Now you do. Meet KWESST Micro Systems. Watch this great interview with David Luxton himself to learn more about KWE and why it just received a follow-on order for $1.1 Million from a key US Military Customer. We’d tell you who it is but we’d then have to release KWE micro drones …. you know the rest.

Watch this interview or listen by Podcast on Apple, Google, Spotify or your favourite podcaster.

Tags: CSE, defense stocks, investing, military, Samsung, small cap stocks, stocks, TASCS
Posted in AGORACOM Via Satellite, KWESST Micro Systems Inc. | Comments Off on VIDEO – KWESST Micro Systems $KWE.ca Soldier Launched Micro Drones, Electronic Soldier Decoys and a $1.1 Million Dollar Follow-On Order From A Key US Military Customer $WRTC $BYRN.ca $PAT.ca $POWW

POET $PTK.ca $POETF Announces Industry-First Flip-Chip DML Lasers

Posted by AGORACOM-JC at 8:16 AM on Thursday, December 17th, 2020

Enables the World’s Lowest-Cost and Smallest 100G CWDM4 Optical Engine

Completed and tested its high-speed Directly Modulated Laser (DML) designs using a distributed feedback (DFB) structure and successfully “flip-chipped” these lasers onto the Company’s Optical Interposer platform, which also incorporates several other industry-first accomplishments.
flip-chip assembly technique enables a true single-chip, fully integrated Optical Engine to be produced at wafer-scale, resulting in the lowest-cost, smallest-size 100G CWDM4 Optical Engine with a form factor of 9mm x 6mm, while including banks of four lasers, four monitor photodiodes, four high speed photodiodes, a multiplexer, demultiplexer, taps for power monitoring and features supporting a self-aligned fiber attach unit.

TORONTO, Dec. 17, 2020 — POET Technologies Inc. (“POET” or the “Company”) (TSX Venture: PTK; OTCQX: POETF) the designer and developer of the POET Optical Interposer™ and Photonic Integrated Circuits (PICs) for the data center and tele-communication markets, announced today that it has completed and tested its high-speed Directly Modulated Laser (DML) designs using a distributed feedback (DFB) structure and successfully “flip-chipped” these lasers onto the Company’s Optical Interposer platform, which also incorporates several other industry-first accomplishments.

The flip-chip assembly technique enables a true single-chip, fully integrated Optical Engine to be produced at wafer-scale, resulting in the lowest-cost, smallest-size 100G CWDM4 Optical Engine with a form factor of 9mm x 6mm, while including banks of four lasers, four monitor photodiodes, four high speed photodiodes, a multiplexer, demultiplexer, taps for power monitoring and features supporting a self-aligned fiber attach unit.

“Without being able to flip-chip the lasers, we would be unable to assemble Optical Engines at wafer-scale, which is the single most important driver of cost. Wafer-scale processing enables the production of high unit volumes at low incremental costs, ultimately allowing us to reduce the cost of building photonics devices by 25% to 40% compared to conventional approaches,” stated Suresh Venkatesan, Chairman and CEO of POET. “Following our successful demonstration of this flip-chip assembly process, POET can now readily incorporate these lasers and other active devices into derivative optical engine configurations, supporting data communications applications such as 200G CWDM4, 100G CWDM6, and 100G LR4, telecom applications such as 5G, as well as other applications that could benefit from the small size and low cost of our platform technology.”

Four DML lasers are commonly used in 100G transceiver applications, a key initial target market for POET’s Optical Interposer, enabling high speed optical communication in the 2 to 10 km range. Operating at speeds of 25 gigabits per second (GPS), POET’s family of four DML lasers of different wavelengths are the first known commercial 25G DFB-type DML lasers to utilize a flip-chip process to passively align and bond to electronic and optical circuitry on the interposer platform, while maintaining optimal performance. Given the estimated total available market (TAM) for 100G transceivers of approximately $2.5 billion, POET believes that its recently formed JV company, SuperPhotonics Xiamen, can achieve annual revenue of over $100 million within this single market segment in the 2024-25 time frame.

Flip-chip assembly of electronic devices on circuit boards, MEMS (Microelectromechanical Systems) and other devices is an advanced manufacturing process for achieving electrical interconnect (often referred to as 2-D, 2.5-D and 3-D) in semiconductor architectures. To achieve the benefits of the planar architecture of POET’s Optical Interposer that facilitates wafer-scale processing, flip-chipping of lasers was an important development milestone, requiring POET to demonstrate that it could simultaneously optimize the RF (radio frequency) performance of the flip-chipped DML laser on interposer while preserving a low RIN (relative intensity noise) measurement both before and after assembly. RF performance relates to the quality and power of the electrical signals, while RIN is a measure of stability of the lasers that are assembled on the Interposer.

“Beyond The Press Release”

POET Technologies goes “Beyond The Press Release” to discuss today’s news. Shareholders and other interested parties are encouraged to check back on this link before market open on the morning of Tuesday December 22, 2020.

https://agoracom.com/ir/POETTechnologies/forums/discussion/topics/751215-poet-technologies-goes-beyond-the-press-release/messages/2293211#message

About POET Technologies Inc.
POET Technologies is a design and development company offering integration solutions based on the POET Optical Interposer™ a novel platform that allows the seamless integration of electronic and photonic devices into a single multi-chip module using advanced wafer-level semiconductor manufacturing techniques and packaging methods. POET’s Optical Interposer eliminates costly components and labor-intensive assembly, alignment, burn-in and testing methods employed in conventional photonics. The cost-efficient integration scheme and scalability of the POET Optical Interposer brings value to any device or system that integrates electronics and photonics, including some of the highest growth areas of computing, such as Artificial Intelligence (AI), the Internet of Things (IoT), autonomous vehicles and high-speed networking for cloud service providers and data centers. POET is headquartered in Toronto, with operations in Allentown, PA and Singapore. More information may be obtained at www.poet-technologies.com .

Shareholder Contact for POET:
Shelton Group
Brett L. Perry
[email protected]

Company Contact for POET:
Thomas R. Mika, EVP & CFO
[email protected]

This news release contains “forward-looking information” (within the meaning of applicable Canadian securities laws) and “forward-looking statements” (within the meaning of the U.S. Private Securities Litigation Reform Act of 1995). Such statements or information are identified with words such as “anticipate”, “believe”, “expect”, “plan”, “intend”, “potential”, “estimate”, “propose”, “project”, “outlook”, “foresee” or similar words suggesting future outcomes or statements regarding any potential outcome. Such statements include the Company’s expectations with respect to the success of the Company’s product development efforts, the performance of its products, the expected results of its operations, meeting revenue targets, and the expectation of continued success in the financing efforts, the capability, functionality, performance and cost of the Company’s technology as well as the market acceptance, inclusion and timing of the Company’s technology in current and future products.

Such forward-looking information or statements are based on a number of risks, uncertainties and assumptions which may cause actual results or other expectations to differ materially from those anticipated and which may prove to be incorrect. Assumptions have been made regarding, among other things, management’s expectations regarding the success and timing for completion of its development efforts, financing activities, future growth, recruitment of personnel, opening of offices, the form and potential of its planned joint venture, plans for and completion of projects by the Company’s third-party consultants, contractors and partners, availability of capital, and the necessity to incur capital and other expenditures. Actual results could differ materially due to a number of factors, including, without limitation, the failure of its products to meet performance requirements, operational risks in the completion of the Company’s anticipated projects, a delay or abandonment of its planned joint venture, delays in recruitment for its newly opened operations or changes in plans with respect to the development of the Company’s anticipated projects by third-parties, risks affecting the Company’s ability to execute projects, the ability of the Company to generate sales for its products, the ability to attract key personnel, and the ability to raise additional capital. Although the Company believes that the expectations reflected in the forward-looking information or statements are reasonable, prospective investors in the Company’s securities should not place undue reliance on forward-looking statements because the Company can provide no assurance that such expectations will prove to be correct. Forward-looking information and statements contained in this news release are as of the date of this news release and the Company assumes no obligation to update or revise this forward-looking information and statements except as required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

120 Eglinton Avenue, East, Suite 1107, Toronto, ON, M4P 1E2- Tel: 416-368-9411 – Fax: 416-322-5075

Tags: AI, Cloud Computing, lightbar, photonics, small cap, small cap stocks, stocks, tech
Posted in POET Technologies | Comments Off on POET $PTK.ca $POETF Announces Industry-First Flip-Chip DML Lasers

CardioComm Solutions $EKG.ca to Bring #ECG Monitoring to Remote Patient and #COVID-19 Monitoring Platforms $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

Posted by AGORACOM-JC at 8:38 PM on Tuesday, December 15th, 2020

Entered into a technology integration agreement with LiveCare Corp. and a Value-Added Reseller and Distribution Agreement with Alliance Tele-Med, to provide integrated ECG monitoring through the LiveCare Link+ device and telemedicine platform.
CardioComm confirms integration of their FDA and Health Canada cleared GEMS™ ECG management software, the wireless HeartCheck™ CardiBeat ECG monitor and access to the SMART Monitoring ECG reading service into the Link+ platform has been completed.
Under the agreement, the GEMS™ Mobile app technology was embedded into the Link+ gateway device allowing ECGs to be transferred through the Link+ platform to the CardioComm SMART Monitoring ECG reading service.
Once an ECG report is completed, the report findings are then securely transmitted to the Link+ platform and from there to the Link+ platform’s remote patient monitoring teams.

TORONTO, ON / December 15, 2020 / CardioComm Solutions, Inc. (TSXV:EKG) (“CardioComm” or the “Company“), a global provider of consumer heart monitoring and electrocardiogram (“ECG“) device and software solutions, is pleased to confirm it has entered into a technology integration agreement with LiveCare Corp. (“LiveCare“) and a Value-Added Reseller and Distribution Agreement with Alliance Tele-Med (“Alliance“), to provide integrated ECG monitoring through the LiveCare Link+ device and telemedicine platform.

CardioComm confirms integration of their FDA and Health Canada cleared GEMS™ ECG management software, the wireless HeartCheck™ CardiBeat ECG monitor and access to the SMART Monitoring ECG reading service into the Link+ platform has been completed. Under the agreement, the GEMS™ Mobile app technology was embedded into the Link+ gateway device allowing ECGs to be transferred through the Link+ platform to the CardioComm SMART Monitoring ECG reading service. Once an ECG report is completed, the report findings are then securely transmitted to the Link+ platform and from there to the Link+ platform’s remote patient monitoring teams.

Link+ is a patented smart home gateway that integrates multiple key medical bio-sign monitoring devices in a patient’s home through a proprietary, touch-free device which is always connected to the 4G network. There is no need for patients to connect to any specific Wi-Fi network for the Link+ to fully operate and, once activated, the Link+ transmits data directly to LiveCare’s HIPAA compliant cloud. The Link+ is fully reimbursable through Medicare, Medicaid and many commercial insurance plans using multiple CPT codes.

Through the addition of the GEMS™ technology into the Link+ gateway device, the Link+ device will be capable of recognizing multiple ECG devices with up to 12 leads of ECG recording and provide Link+ customers with more options in choosing a device of their preference. The HeartCheck™ CardiBeat will be the recommended device for remote ECG patient monitoring given its availability in Canada, the US and Europe. All recorded ECGs will be passed through CardioComm’s SMART Monitoring ECG triaging service. ECG reports confirming the presence or absence of an arrhythmia will be provided to Link+ users.

The Link+ platform with ECG monitoring sales and marketing will be undertaken exclusively by Alliance with a focus on monitoring patients with or suspected to have COVID-19. Sales into the US is where the primary marketing efforts are targeted for 2021. CardioComm will see revenue from the sales of the HeartCheck™ CardiBeat ECG devices as well as from ECG triaging service fees.

To learn more about CardioComm’s products and for further updates regarding HeartCheck™ ECG device integrations please visit the Company’s websites at www.cardiocommsolutions.com and www.theheartcheck.com.

About CardioComm Solutions

About LiveCare (www.livecareusa.com)

LiveCare’s mission is to improve patient outcomes, lower healthcare costs, and reduce hospital readmissions by developing technology to assist patients and providers during the critical transitional care period. LiveCare’s technology improves patient compliance with post-discharge medical protocols and enhances engagement between patients and providers. With a team of experienced professionals working in research and development, sales, and other capacities, LiveCare is putting the needs of patients and providers at the forefront as it moves the RPM market forward from its corporate headquarters in New York City.

About Alliance-Telemed, LLC

Alliance Tele-Med is a US-based Value-Added Wholesaler & Reseller of state-of-the-art remote patient monitoring (RPM) technology and care management services solutions for domestic and international healthcare delivery organizations and their patients. The company engages with healthcare and life sciences organizations such as Independent and Hospital-Owned Medical Practices, Independent Hospitals and Health Systems, Accountable Care Organizations (ACO’S), Independent Physician Associations (IPA’s), Provider Networks, large Employer Groups and Third Party Administrators, Clinics, FQHC and Regional Health Centers, Senior ‘Aging in Place’ Companies and Facilities such as Assisted Living Facilities, Nursing Homes, Skilled Nursing Facilities, Home Health Companies, pharmaceutical companies, and Clinical Research Organizations (CRO’s).

FOR FURTHER INFORMATION PLEASE CONTACT:

Etienne Grima, Chief Executive Officer
1-877-977-9425 x227
[email protected]
[email protected]

Forward-looking statements

Tags: CardioComm SMART Monitoring ECG reading, CSE, ECG, GEMS™ ECG, investments, mhealth, small cap stocks, Smart apps
Posted in CardioComm Solutions | Comments Off on CardioComm Solutions $EKG.ca to Bring #ECG Monitoring to Remote Patient and #COVID-19 Monitoring Platforms $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

KWESST $KWE.ca Extends Option to Acquire Non-Lethal Technology $WRTC $BYRN.ca $PAT.ca $POWW

Posted by AGORACOM-JC at 7:47 AM on Tuesday, December 15th, 2020

Announced it has extended until January 15, 2021 its option to acquire a proprietary non-lethal munitions technology system referred to as the Low Energy Cartridge technology
The owner of the LEC Technology is DEFSEC Corporation (“DEFSEC”), an Ottawa-based based private company owned by David Luxton the Executive Chairman of KWESST.
KWESST entered into a letter of intent with DEFSEC on June 6, 2020 to acquire the LEC Technology.
The parties continue to cooperate and are working toward a definitive agreement.

Ottawa, Ontario–(December 15, 2020) – KWESST Micro Systems Inc. (TSXV: KWE) (“KWESST” or “the Company”) today announced it has extended until January 15, 2021 its option to acquire a proprietary non-lethal munitions technology system referred to as the Low Energy Cartridge technology (“LEC Technology”).

The owner of the LEC Technology is DEFSEC Corporation (“DEFSEC”), an Ottawa-based based private company owned by David Luxton the Executive Chairman of KWESST. KWESST entered into a letter of intent with DEFSEC on June 6, 2020 to acquire the LEC Technology. The parties continue to cooperate and are working toward a definitive agreement.

The LEC Technology is a proprietary non-lethal cartridge-based ordnance system with wide application in the rapidly growing market of soldier and law enforcement training, maintenance of public order, personal defence, and high-action gaming. “The market has long required a safer, lower-cost reliable alternative to existing solutions,” said Jeff MacLeod, KWESST Founder and CEO. “We see the LEC Technology as a strong fit with KWESST’s other smart ordnance technologies, like our Shot Counter system. Together, the LEC Technology and Shot Counter have the potential to anchor the build-out of a significant business unit specialized in smart ordnance systems, with a vast global market.”

The contemplated transaction would benefit from the deep combined experience of Jeff MacLeod and David Luxton in the specialty ordnance business. Mr. MacLeod is a highly knowledgeable defence industry executive with over 20 years’ experience in the field of small arms and advanced soldier systems. Prior to establishing KWESST, he was the General Manager of Colt Canada, the primary supplier of small arms to the Canadian military. David Luxton was the founder in 1990 of Simunition Inc., a business that develops and sells simulated munitions for realistic close quarters combat training for military and law enforcement around the world. He sold the business to a large military contractor and from 2015 – 2018 was the Executive Chairman of United Tactical Systems LLC, a U.S. company that develops and sells products for the global less-lethal market.

The purchase price for the LEC Technology shall be satisfied by the issuance to DEFSEC of 1,000,000 shares of KWESST and 500,000 share purchase warrants of KWESST at a price of $0.70 per share. The warrants shall vest as to 25% on the first anniversary of the closing of the LEC Technology acquisition and 25% on each of the subsequent three anniversaries of the completion of the LEC Technology acquisition. DEFSEC shall also be entitled to a 7% royalty on annual sales of the LEC Technology, net of taxes, duties, customs brokerage fees, shipping and handling costs, customer credits, discounts and returns, up to a cumulative maximum of $10 million. The other terms and conditions of the letter of intent between DEFSEC and KWESST are detailed on pages 16 and 17 of the Company’s Filing Statement dated September 28, 2020 which can be found at www.sedar.com. The acquisition of the LEC technology by KWESST remains subject to the approval of the TSX Venture Exchange.

The Company has granted to each of its three independent directors 250,000 stock options pursuant to the Company’s stock option plan. The stock options will vest over a two-year period and may be exercised at a closing price of the Company’s shares on the TSX Venture Exchange on December 15, 2020. The options will be outstanding for a period of five years from the date of grant. The Company has finalized the shares for debt described in its November 25, 2020 news release.

About KWESST

KWESST develops and commercializes high-value ultra-miniaturized technology applications that make a critical difference to the safety and operational effectiveness of personnel in the defence and security industries. The company’s current portfolio of unique proprietary offerings include: its signature TASCSTM (Tactical and Situational Control System) for real-time awareness and targeting information from any source (including drones) streamed directly to users’ smart devices and weapons; the autonomous GreyGhostTM soldier-portable micro drone missile system that defends against small hostile drones including swarms using high-speed kinetic impact; a Ground Laser Defence system to counter the emerging threat of weaponized lasers against personnel; and, the PhantomTM electronic battlefield decoy system to mask the electromagnetic signature of friendly forces with decoy signatures at false locations to deceive and confuse adversaries. All systems can operate stand-alone or integrate seamlessly with OEM products and battlefield management systems including Frontline, Edge, Killswitch and ATAK (Android Tactical Assault Kit) among others. KWESST also has developmental “smart ordnance” projects including its “Shot Counter” system, which records the number and type of rounds fired, for optimized firearms maintenance and performance. The Company is headquartered in Ottawa, Canada, with representative offices in Washington, DC, London, UK and Abu Dhabi, UAE. KWESST trades on the TSX Venture Exchange under the symbol KWE.

Contact: Jason Frame, Investor Relations: [email protected]

For more information, please visit https://kwesst.com/

Cautionary Note Regarding Forward-Looking Statements

This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to the timing for the commencement of trading and the plans and operations of KWESST after giving effect to the Qualifying Transaction. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. KWESST disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/70231

Tags: CSE, defense stocks, investing, military, Samsung, small cap stocks, stocks, TASCS
Posted in KWESST Micro Systems Inc. | Comments Off on KWESST $KWE.ca Extends Option to Acquire Non-Lethal Technology $WRTC $BYRN.ca $PAT.ca $POWW

Kontrol Energy $KNR $KNR.ca $KNR.c $KNRLF Enters into Distribution Agreement with Grande West to Offer BioCloud Technology Covid-19 Detection Systems for Vicinity Buses $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Posted by AGORACOM-JC at 7:26 AM on Tuesday, December 15th, 2020

Entered into a distribution agreement with Grande West, a Canadian manufacturer of mid-sized multi-purpose transit vehicles for sale in Canada and the United States, to offer BioCloudTM technology to the Vicinity line of buses.
Under the terms of the non-exclusive distribution agreement, Grande West will offer the BioCloud solution as an option in its Vicinity LightningTM, Vicinity LT and Vicinity heavy duty bus specifications.
Grande West’s existing customers will be notified of the option to retrofit the BioCloud devices into existing fleets across Canada.

TORONTO, ON / December 15, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“) is pleased to announce that it has entered into a distribution agreement with Grande West, a Canadian manufacturer of mid-sized multi-purpose transit vehicles for sale in Canada and the United States, to offer BioCloudTM technology to the Vicinity line of buses.

“We are pleased to enter into this agreement with Grande West as we continue to target the important sector of ground transportation with an established and successful bus OEM. We are excited to be working with another disruptive Canadian company, focusing on a transit solution that will make buses safer and reduce risk of potential viral spread for the riders,” stated Paul Ghezzi, CEO Kontrol Energy. “We anticipate that this additional partnership will add another channel for incremental sales as the need for safe detection of airborne viruses in public spaces grows.”

Under the terms of the non-exclusive distribution agreement, Grande West will offer the BioCloud solution as an option in its Vicinity LightningTM, Vicinity LT and Vicinity heavy duty bus specifications. Grande West’s existing customers will be notified of the option to retrofit the BioCloud devices into existing fleets across Canada. United States customers will be serviced by working with Kontrol Energy’s exclusive distributor, United Safety and Survivability Corporation. Pricing will not be disclosed for industry competitive purposes.

William Trainer, President & CEO of Grande West stated, “Grande West is proud to be partnering with Kontrol in working towards making our Vicinity buses safer for all of our end users. The Company is expanding its product lines into Electric Vehicles and lighter duty models and ramping up its U.S. sales and expects significant growth in the coming years. We will do everything we can to offer the safest and most effective transit solutions to our customers.”

As an initial step, Grande West is immediately ordering two of BioCloud units for its offices and operations headquarters in Aldergrove to improve the safety considerations of its employees.

About BioCloudTM

BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, offices, retirement homes, hospitals, mass transportation and others.

Additional information about Kontrol BioCloud can be found on its website at www.kontrolbiocloud.com

BioCloud is an air quality technology and not a medical device. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).

About Kontrol Energy

Kontrol Energy Corp., a Canadian public company, is a leader in smart buildings and cities through IoT, Cloud and SaaS technology. Kontrol Energy provides a combination of software, hardware, and service solutions to its customers to improve energy management, air quality and continuous emission monitoring.

Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at: www.sedar.com

About Grande West Transportation Group

Grande West Transportation is a Canadian company that designs and engineers mid-size multi-purpose transit vehicles for public and commercial enterprises. Grande West utilizes world-class manufacturing partners to produce the Purpose-Built VicinityTM medium and heavy-duty buses available in electric, CNG, gas and clean diesel drive systems. The Vicinity LightningTM EV with an electric propulsion drive system is available for 2021 deliveries.

The Company has been successful in supplying Canadian municipal transportation agencies and private operators with new buses. Grande West is compliant to Buy America certification, and with a strong distribution chain in the U.S., is actively pursuing opportunities in public and private transit fleet operations that would benefit from Grande West’s vehicles.

www.grandewest.com

www.vicinitybus.com

For further information, contact:

Paul Ghezzi, Chief Executive Officer
[email protected] or [email protected]
Kontrol Energy Corp.
180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8
Tel: 905.766.0400, Toll free: 1.844.566.8123

Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.

However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloudTM (“BioCloud”) are subject to the risk that the Kontrol BioCloud may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.

Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.

SOURCE: Kontrol Energy Corp.

Tags: BioCloud, COVID-19, CSA, CSA Standards, CSE, energy conservation, google nest, small cap, small cap stocks, stocks, tsx
Posted in Featured, Kontrol Energy Corp. | Comments Off on Kontrol Energy $KNR $KNR.ca $KNR.c $KNRLF Enters into Distribution Agreement with Grande West to Offer BioCloud Technology Covid-19 Detection Systems for Vicinity Buses $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

MedX Health Corp. $MDX.ca Announces the Rollout of DermSecure® in the Netherlands $DMTK $LMD.ca $DOC.ca $DOCRF $WELL.ca $PRN.ca

Posted by AGORACOM-JC at 8:13 PM on Monday, December 14th, 2020

Highlights:

MedX partners with national telehealth leader IVPG in the Netherlands
Two skin screening clinics opened in November 2020, with more than 800 assessments on close to 500 patients completed to date using MedX’s DermSecure ® platform
Three additional clinics to come online in the Netherlands by the end of December 2020
IVPG plans to expand to 41 skin assessment clinics by 2022
More than half of all cancers reported in the Netherlands are skin cancers

MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX), a global leader in teledermatology, announces that it has begun the rollout of DermSecure ® , MedX’s skin screening telemedicine platform, across the Netherlands in partnership with national telehealth leader The Netherlands Institute for Prevention and Health (“IVPG”).

“Telehealth allows us to assess patients, relay test results and provide video consultations with IVPG doctors, ultimately offering greater access to medical specialists during the COVID-19 crisis,” commented Paul Vlaanderen, IVPG Founder & CEO. “This improved access to healthcare specialists has directly resulted in higher quality care and the ability for patients to play a greater role in their healthcare management. We opened two locations in November and experienced substantial interest in the skin screening service, completing over 800 assessments on nearly 500 patients so far, and the DermSecure platform worked flawlessly. We will add another three locations, Rotterdam, Utrecht and Den Haag, to our IVPG network in 2020. IVPG further plans to bring the total number of scanning centers to 41 by 2022.”

“According to the World Cancer Research Fund, the Netherlands is ranked fifth globally for melanoma skin cancer. We know that early detection of skin cancer results in lower mortality rates, lower health care costs and much better patient outcomes. MedX’s advanced imaging technology and secure, scalable, teledermatology platform was a perfect fit to address the need for rapid skin screening in the Netherlands,” continued Mr. Vlaanderen.

Naman Demaghlatrous, MedX’s Managing Director, Europe, Middle East and Africa, was very impressed with the results of the implementation, stating, “Building on our pilot project with IVPG, DermSecure ® provides the requisite security and scalability to open multiple centers and expand this partnership significantly. We are honoured to work with Mr. Vlaanderen as he has been a pioneer in championing telehealth in the Netherlands. We look forward to playing a crucial role in enhancing Netherlanders’ access to early screening and thereby reduce skin cancer deaths.”

About MedX

MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy ® on DermSecure ® telemedicine platform, utilizing its SIAscopy ® technology. SIAscopy ® is also embedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain-free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com

About IVPG

IVPG is a Netherlands based Institute for Prevention and Health using telehealth for the delivery of digital healthcare. We are a collaboration of doctors and specialists. Together we help the Dutch to live a healthy and energetic life. IVPG provides the Dutch people with health information, free preventive examinations and advice to give more in-depth insight into their health. Although we are not always in control of our health, we can often manage it. That is our commitment. www.ivpg.nl

Forward-Looking Statements

This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company’s limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company’s projections or forward-looking statements. All forward-looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201214005867/en/

Investor Relations
Bill Mitoulas
[email protected]
Tel: +1.416.479.9547

Tags: DermSecure, MedX, MoleMate, Simsys, Skin Cancer, small cap stocks, stocks, telehealth
Posted in MedX Health Corporation | Comments Off on MedX Health Corp. $MDX.ca Announces the Rollout of DermSecure® in the Netherlands $DMTK $LMD.ca $DOC.ca $DOCRF $WELL.ca $PRN.ca

VIDEO – Mountain Valley MD $MVMD.ca Catches Small Cap Fire After #Ivermectin Testimony In US Senate Called “Miraculous Effectiveness” In Prohibiting Transmission Of #COVID-19

Posted by AGORACOM-JC at 4:19 PM on Monday, December 14th, 2020

“It basically obliterates transmission of this virus”

This was the testimony of Pierre Kory, M.D., Associate Professor of Medicine at St. Luke’s Aurora Medical Center, delivers passionate testimony during the Senate Homeland Security and Governmental Affairs Committee hearing on “Early Outpatient Treatment: An Essential Part of a COVID-19 Solution, Part II.”

We interviewed Leigh Hughes, newly appointed Advisor to MVMD who will be supporting the Company in the areas of M&A, corporate finance and pharmaceutical licensing, to provide us with further insight as to why the testimony of Dr. Kory is so relevant to MVMD … and why Dr. Kory actually called MVMD last week to discuss the Company’s involvement with Ivermectin.

Mountain Valley MD has traded over 50,000,000 shares in the last 3 trading days, so there is a clear need for information amongst retail investors.

Tags: COVID-19, Ivermectin, small cap, small cap stocks, stocks, tsx, tsx-v
Posted in AGORACOM Via Satellite, All Recent Posts, Featured, Mountain Valley MD | Comments Off on VIDEO – Mountain Valley MD $MVMD.ca Catches Small Cap Fire After #Ivermectin Testimony In US Senate Called “Miraculous Effectiveness” In Prohibiting Transmission Of #COVID-19

KWESST $KWE.ca Announces C$1.1 Million Follow-on Order For TASCS IFM From Key U.S. Military Customer $WRTC $BYRN.ca $PAT.ca $POWW

Posted by AGORACOM-JC at 7:41 AM on Monday, December 14th, 2020

Announced a follow-on order for approximately C$ 1.1 million with a key U.S. military customer to expand use of the Company’s TASCS IFM system in military exercises, a key precursor to wider adoption
contract is for application of the TASCS IFM system on the 81mm mortar platform, which transforms it into a “smart” weapon system with greater accuracy and faster response time, improving soldier survivability and operational effectiveness.
Work under the order is scheduled to commence immediately.
Founder, President and CEO Jeff MacLeod commented that, “This marks another key validating milestone in a market where TASCS IFM on the 81mm mortar alone could ultimately be worth up to C$120 million in the U.S. and another C$400 million worldwide, given the large installed base of 81mm mortars in service with so many NATO and allied military forces.”

Ottawa, Ontario–(December 14, 2020) – KWESST Micro Systems Inc. (TSXV: KWE) (“KWESST” or “the Company”) today announced a follow-on order for approximately C$ 1.1 million with a key U.S. military customer to expand use of the Company’s TASCS IFM system in military exercises, a key precursor to wider adoption.

The contract is for application of the TASCS IFM system on the 81mm mortar platform, which transforms it into a “smart” weapon system with greater accuracy and faster response time, improving soldier survivability and operational effectiveness. Work under the order is scheduled to commence immediately.

KWESST Founder, President and CEO Jeff MacLeod commented that, “This marks another key validating milestone in a market where TASCS IFM on the 81mm mortar alone could ultimately be worth up to C$120 million in the U.S. and another C$400 million worldwide, given the large installed base of 81mm mortars in service with so many NATO and allied military forces.”

KWESST previously announced the completion of an earlier two-phase initial contract with the same customer that marked the introduction of TASCS IFM on 81mm mortars in military exercises. “It is very encouraging to see the accelerated pace at which this important customer is expanding the use of TASCS IFM in its field exercises, and their confidence in KWESST,” added MacLeod. “It is an honor to be working with them to enhance soldier survivability and effectiveness, which is our core mission.”

As previously announced, the TASCS IFM system has attracted interest from other NATO forces who have requested proposals from KWESST, which the Company is currently actioning. “The fact that the TASCS IFM confers so many modernization advantages without any modification to weapon platforms or munitions is a huge attraction,” said MacLeod.

He added that, “The 81mm mortar is just one of many different weapon platforms that can be transformed into a smart system with TASCS IFM, providing soldiers on the ground with real-time networked situational awareness and precision targeting information.” Accordingly, KWESST is pursuing additional global markets for the TASCS IFM, which can also work on platforms such as: 60mm mortars; grenade launchers; sniper rifles; drones; electronic decoys; and more, with a total addressable market of more than C$1 billion.

About KWESST

Contact: Jason Frame, Investor Relations: [email protected]

For more information, please visit https://kwesst.com/

Cautionary Note Regarding Forward-Looking Statements

This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to the plans and operations of KWESST. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to general business, economic, competitive, political and social uncertainties. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. KWESST disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Image: TASCS IFM System on M252 (81mm)

To view an enhanced version of this image, please visit:
https://orders.newsfilecorp.com/files/7366/70148_ccd0de0d64153b68_001full.jpg

Tags: CSE, defense stocks, investing, military, Samsung, small cap stocks, stocks, TASCS
Posted in KWESST Micro Systems Inc. | Comments Off on KWESST $KWE.ca Announces C$1.1 Million Follow-on Order For TASCS IFM From Key U.S. Military Customer $WRTC $BYRN.ca $PAT.ca $POWW

Posts Tagged ‘small cap stocks’

Enables the World’s Lowest-Cost and Smallest 100G CWDM4 Optical Engine

Categories